Tampa, FLNCT07015242Now EnrollingIRB Ready

Primary Central Nervous System Lymphoma Clinical Trial in Tampa, FL

Access cutting-edge primary central nervous system lymphoma treatment through this phase 2 clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Quick Self-Assessment

See if you qualify for this Tampa location

Preparing your pre-screening questions…

Expert Care in Tampa

Access primary central nervous system lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related primary central nervous system lymphoma treatment provided free

Apply for This Tampa Location

Check if you qualify for this primary central nervous system lymphoma clinical trial in Tampa, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tampa

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tampa site if eligible
  4. 4Begin participation

About This Primary Central Nervous System Lymphoma Study in Tampa

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Who Can Participate

Inclusion Criteria

Participant must be 18 years or older at the time of signing the informed consent form (ICF).
Histologically confirmed primary central nervous system (CNS) lymphoma (PCNSL) prior to screening, as assessed by local pathology.
Transplant-ineligible based on physician's assessment and meeting at least one of the following criteria: age ≥65 years or HCT-CI (Hematopoietic Cell Transplantation-specific Comorbidity Index) score ≥3.
Participant must be suitable, per investigator, to receive a high dose methotrexate (HD-MTX) based treatment regimen.
Prior to signing ICF, anti-cancer therapy for the treatment of PCNSL must be limited to HD-MTX based standard of care regimens with a minimum of 4 and maximum of 6 doses of MTX. Corticosteroids used as part of standard-of-care management for PCNSL symptom control are permitted prior to ICF signature but must be discontinued at the time of ICF signature. For medical conditions other than PCNSL, non-therapeutic corticosteroids use may be permitted on study.
Prior to enrollment, participant's disease must be sensitive to prior high-dose methotrexate-based (HD-MTX) regimens, as demonstrated by a complete response (CR, no remaining signs of PCNSL) or a partial response (PR, signs of PNCSL mostly gone) per Investigator's assessment, based on the International Primary CNS Lymphoma Collaborative Group (IPCG) criteria.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
No prior experimental treatments for PCNSL.
Individuals of childbearing potential (IOCBP) must have a negative highly sensitive pregnancy test within 24 hours prior to the start of study intervention.

Exclusion Criteria

Participant has a diagnosis of secondary CNS lymphoma due to systemic disease.
Primary intraocular lymphoma (PIOL)/ Primary vitreoretinal lymphoma (PVRL), isolated cerebrospinal fluid (CSF) disease, or a relapsed or refractory PCNSL.
Any significant medical condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she was to participate in the study based on investigator's judgement.
History of another primary malignancy that has not been in remission for ≥2 years. a. Exceptions include certain adequately treated non-invasive malignancies, localized prostate cancer treated with curative intent, and completely resected Stage 1 solid tumors with a low risk of recurrence.
Prior treatment with CAR T-cell or any other gene therapy product that utilizes human genome-editing technology.
History of or active human immunodeficiency virus (HIV).
Active hepatitis B or active hepatitis C.
Active autoimmune disease requiring immunosuppressive therapy.
History of prior allogeneic transplant, or solid organ transplant requiring immunosuppressive therapy.
Other protocol-defined Inclusion/Exclusion criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT07015242) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Central Nervous System Lymphoma Treatment Options in Tampa, FL

If you're searching for primary central nervous system lymphoma treatment options in Tampa, FL, this clinical trial (NCT07015242) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced primary central nervous system lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary central nervous system lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Tampa, FL

See all lymphoma clinical trials recruiting in Tampa — not just this study.

Browse Lymphoma Trials in Tampa →

Browse More Trials by Condition

Lymphoma TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Tampa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tampa, FL